Source comparison
CJC-1295 Peptide: DAC vs Non-DAC Comparison
Half-Life 6–8 days ~30 minutes DAC formulation allows once or twice-weekly dosing vs multiple daily administrations. Critical for long-term research protocols Albumin Binding Yes (via maleimidoproprionic acid linker) No Albumin binding is what creates the exte
This comparison does not assign a generated winner or score.
- Half-Life
- 6–8 days
- ~30 minutes
- DAC formulation allows once or twice-weekly dosing vs multiple daily administrations. Critical for long-term research protocols
- Albumin Binding
- Yes (via maleimidoproprionic acid linker)
- No
- Albumin binding is what creates the extended reservoir effect. Without it, the peptide is cleared rapidly despite DPP-4 resistance
- Dosing Frequency
- 1–2 times per week
- 1–3 times per day
- Non-DAC formulations require coordination with meal timing and sleep cycles to capture endogenous GH pulse windows
- Typical Research Dose
- 1–2 mg per administration
- 100–200 mcg per administration
- Dosing reflects pharmacokinetic differences. DAC formulations accumulate, non-DAC formulations clear within hours
- Combination Use
- Often used alone or with daily GHRP
- Nearly always combined with GHRP (ipamorelin, GHRP-2) for synergistic pulsatile effect
- Mod GRF 1-29's short half-life makes it ideal for acute pulse amplification when timed with GHRP dosing
- Storage Stability
- Lyophilised form stable at −20°C; reconstituted form requires refrigeration at 2–8°C
- Same storage requirements. Both formulations are peptides subject to degradation at room temperature
- DAC modification does not change storage requirements. Both require cold chain integrity